At Trinity College Dublin, researchers have cracked open a cellular riddle that has long puzzled TB specialists: why some people successfully contain tuberculosis for years while others spiral into active disease. The answer lies in how immune cells burn energy.
The discovery, published in the Journal of Infection, reveals that immune cells in people with latent tuberculosis possess a kind of metabolic flexibility—a cellular adaptability that keeps the infection locked down. By contrast, the same immune cells in people with active TB disease show signs of metabolic exhaustion and fail to mount effective resistance. This finding offers the clearest picture yet of what separates controlled infection from disease progression.
Tuberculosis remains the world's leading infectious killer, claiming 1.25 million lives in 2023 alone from 10.8 million reported cases. Yet the disease's behavior is strangely contradictory: most people infected with Mycobacterium tuberculosis never fall ill, their immune systems quietly containing the pathogen in what's called latent infection. Others cannot hold the line, and active disease develops. Until now, the immunological reasons for this divide have remained largely opaque.
Dr. Gráinne Jameson, the postdoctoral researcher in immunology who led the study at Trinity Translational Medicine Institute, focused on circulating monocytes—frontline immune cells crucial to fighting TB. Her team performed single-cell metabolic profiling, examining how these cells generated and deployed energy. The contrast was striking. In latent TB, monocytes remained metabolically flexible, capable of rapid antimicrobial responses. In active disease, these same cells showed impaired metabolism and weakened ability to fight infection.
"In people with latent TB, these immune cells appear metabolically adaptable and ready to respond to infection," Jameson explained. "In active TB disease, however, the same cells show signs of dysfunction and are less capable of mounting an effective immune response. Latent TB is often thought of as a dormant state, but our findings show the immune system is actively working to keep infection under control."
The research holds immediate practical implications. Current TB treatment is lengthy and grueling, and clinicians lack reliable real-time tools to measure whether a patient's treatment is working. The study found that TB treatment could partially restore healthier immune cell metabolism, suggesting these metabolic signatures might eventually serve as biomarkers for treatment response and disease recovery. Dr. Sharee Basdeo, the principal investigator, sees the potential for transforming how TB is managed. "Our findings suggest that immune metabolism could potentially help us monitor treatment response more precisely and, in the future, may even support more personalized treatment approaches."
This work emerges from a growing global research push into immunometabolism—the intricate dance between how the immune system functions and how cells consume energy. By mapping monocyte metabolism with unprecedented clarity, the Trinity team has provided one of the sharpest comparative views of latent versus active TB infection to date. The implications ripple outward: better monitoring tools, more effective vaccines, and therapies specifically engineered to restore immune cell metabolism could all flow from this foundational understanding. For millions of people living with TB infection worldwide, the discovery opens a new window into why their bodies either prevail or surrender.